Molded Rubber and Plastic Corporation (MRPC) announced its partnership with Vance Street Capital (Vance Street), a Los Angeles-based private equity firm focused on investing in highly engineered solutions. 

This partnership supports MRPC’s continued growth as a full-service medical device contract manufacturer, offering end-to-end capabilities across the medical device community with specialized expertise in silicone and thermoplastic molding solutions.

Founded in 1921 and headquartered in Butler, Wisconsin, with additional facilities in New Hampshire and Florida, MRPC is a family-owned, ISO 13485-certified contract manufacturer of medical devices, instruments, and disposables. 

MRPC provides end-to-end product lifecycle support, from design and development through manufacturing and finished device assembly, backed by vertically integrated capabilities in silicone molding, thermoplastic molding, multi-material molding, cleanroom assembly, packaging, sterilization management, and supply chain services.

Greg Riemer, President, CEO, and shareholder of MRPC, will continue to lead the business alongside the existing management team. 

“We are excited about the next chapter of growth and our partnership with Vance Street. For over 100 years, MRPC has grown into a leading medical device supplier through our expertise in materials and our willingness to take on challenging projects. Finding an investment partner that shared our vision for growth, capability, and capacity expansion while at the same time preserving our employee values was very important to us,” said Riemer.

Over the past several years, Vance Street has partnered with several other complementary businesses in the outsourced medical device manufacturing and service segment, including Motion Dynamics, ViaMed, Applied Plastics, Wytech Industries, Mountain Manufacturing Technologies, Plastic Design Company (PDC), Innovize, and Prince Sterilization Services.

The acquisition represents Vance Street’s sixth platform investment from Vance Street Capital IV L.P. and its sixteenth investment in the medical and life sciences manufacturing space.